Emerald Medical Applications Corp. Announces Its Selection, Among Top Israeli Start-Ups, for Inaugural $100 Million International Venture Capital Competition in Shenzen, China

Mar 21, 2016, 08:30 ET from Emerald Medical Applications Corp.

PETACH TIKVA, Israel, March 21, 2016 /PRNewswire/ --

Emerald Medical Applications Corp. (OTCQB: MRLA), an Israeli-based company engaged in the development and sale of its proprietary "DermaCompare" software app, which everyone can download from the AppStore or Google Store, using, among other devices, digital cameras, camera-equipped smart phones or tablets to capture and transmit total body photography images of skin lesion to enable dermatologists and other medical care professionals to remotely analyze and suspect the presence of skin cancer/Melanoma.

Emerald today announced that of 300 Israeli entries, Emerald was named the 2nd top company, selected as one of the five Israeli technology companies to compete with the five top companies of the 300 entries from each of Silicon Valley, United States, Munich, Germany; Tokyo, Japan; and Sydney, Australia in the Inaugural $100 Million International Innovation Competition, being held in mid-April, 2016 in Shenzhen, China.

The 25 finalists, including Emerald, will be eligible for selection by the presiding judges to receive monetary awards up to $1 million and, more importantly, Emerald will have the opportunity to receive investments out of over $100 million from the participating Shenzhen, China investment funds according to Victor Wang, a Director and Chief Representative of the Shenzhen Economic and Trade Office (SETO).

Lior Wayne, CEO of Emerald, stated "We are exceptionally proud of being selected out of the 300 Israeli entries to be among the finalists to compete in the Inaugural $100 Million International Talents Competition in Shenzhen, China. We believe that our proprietary 'DermaCompare' technology, which we adapted from an Israeli Defense algorithm to identify and suspect Melanoma remotely, represents a significant breakthrough in the early identification and prevention of such a serious disease. Our technology app, using the power of the cloud, to allow medical specialists and their patients the benefits of early detection and treatment of skin cancer/Melanoma. We are very optimistic about the recognition 'DermaCompare' is receiving through our participation in this prestigious competition and the potential rewards it offers."

Lior Wayne further stated that "most recently, Emerald won first place in an international competition 'Brazil Market Potential Healthcare and Biotech Companies' sponsored by the Hospital Isrelito Albert Einstein in Brazil, which first place honor was in addition to Emerald's 2014 awards from IBM, Partner and Axel Springer, the German Media Conglomerate, that invited Emerald to be part of its Scientific Accelerator."

About Emerald Medical Applications Corp 

Emerald Medical Applications Corp., through its wholly-owned Israeli subsidiary, are engaged in the development and sale of its proprietary "DermaCompare" software, using among other devices, digital cameras, camera-equipped smart phones or tablets, to enable dermatologists and other medical care professionals to remotely analyze total body photography images of skin lesion images to diagnose the presence of skin cancer/Melanoma. For more information, visit: http://www.dermacompare.com

Notice Regarding Forward-Looking Statements    

This press release may contain forward-looking statements, about EMERALD's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, EMERALD or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by EMERALD with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of EMERALD's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause EMERALD's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause EMERALD's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in EMERALD's filings with the SEC. In addition, EMERALD operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. EMERALD does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Reference is made to the disclosure under "risk factors" included in our Registration Statement on Form S-1 which was declared effective by the U.S. Securities and Exchange Commission on January 20, 2016.

Contact:
Lior Wayne, CEO
+972-50-6816300
IR@DERMACOMPARE.COM


SOURCE Emerald Medical Applications Corp.